Abstract

Background: Sporadic venous malformation (VM) and angiomatosis of soft tissue (AST) are benign, congenital vascular anomalies affecting venous vasculature. Depending on the size and location of the lesion, symptoms vary from motility disturbances to pain and disfigurement. Due to high recurrence of the lesions more effective therapies are needed.

Methods: As targeting stromal cells has been an emerging concept in anti-angiogenic therapies, here, by using VM/AST patient samples, RNA-sequencing, cell culture techniques and a xenograft mouse model, we investigated the crosstalk of endothelial cells (EC) and fibroblasts and its effect on vascular lesion growth.

Results: We report, for the first time, expression and secretion of transforming growth factor A (TGFA) in ECs or intervascular stromal cells in AST and VM lesions. TGFA induced secretion of VEGF-A paracrinally, and regulated EC proliferation. Oncogenic PIK3CA variant in p.H1047R, a common somatic mutation found in these lesions, increased TGFA expression, enrichment of hallmark hypoxia, and in a mouse xenograft model, lesion size and vascularization. Treatment with afatinib, a pan-ErbB tyrosine-kinase inhibitor, decreased vascularization and lesion size in mouse xenograft model with ECs expressing oncogenic PIK3CA p.H1047R variant and fibroblasts.

Conclusions: Based on the data, we suggest that targeting of both intervascular stromal cells and ECs is a potential treatment strategy for vascular lesions having a fibrous component.

Funding: Academy of Finland, Ella and Georg Ehnrooth foundation, the ERC grants, Sigrid Jusélius Foundation, Finnish Foundation for Cardiovascular Research, Jane and Aatos Erkko Foundation, and Department of Musculosceletal and Plastic Surgery, Helsinki University Hospital.

Data availability

RNA-seq data has been submitted to NCBI Gene Expression Omnibus under accession numbers GSE130807 and GSE196311 (GEO reviewer access tokens; wbivkayaxhojdqp and mbehiikgvtmfryh, respectively).

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Suvi Jauhiainen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  2. Henna Ilmonen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  3. Pia Vuola

    Department of Plastic Surgery, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  4. Heta Rasinkangas

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  5. Heidi H Pulkkinen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  6. Sara Keränen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  7. Miika Kiema

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  8. Jade J Liikkanen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  9. Nihay Laham Karam

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8718-4612
  10. Svetlana Laidinen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  11. Mustafa Beter

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  12. Einari Aavik

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3018-9521
  13. Kimmo Lappalainen

    Department of Radiology, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  14. Jouko Lohi

    Department of Pathology, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  15. Johanna Aronniemi

    Department of Radiology, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  16. Tiit Örd

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  17. Minna U Kaikkonen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6294-0979
  18. Päivi Salminen

    Department of Pediatric Surgery, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  19. Erkki Tukiainen

    Department of Plastic Surgery, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  20. Seppo Ylä-Herttuala

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7593-2708
  21. Johanna P Laakkonen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    For correspondence
    johanna.p.laakkonen@uef.fi
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8556-9727

Funding

Academy of Finland (328835)

  • Johanna P Laakkonen

ERC grant (GA670951)

  • Seppo Ylä-Herttuala

ERC grant (802825)

  • Minna U Kaikkonen

Sigrid Jusélius Foundation

  • Seppo Ylä-Herttuala

Sigrid Jusélius Foundation

  • Minna U Kaikkonen

Finnish Foundation for Cardiovascular Research

  • Johanna P Laakkonen

Finnish Foundation for Cardiovascular Research

  • Seppo Ylä-Herttuala

Finnish Foundation for Cardiovascular Research

  • Minna U Kaikkonen

Jane and Aatos Erkko Foundation

  • Minna U Kaikkonen

Department of Musculosceletal and Plastic Surgery, Helsinki University Hospital

  • Pia Vuola

Academy of Finland (321535)

  • Johanna P Laakkonen

Academy of Finland (353376)

  • Johanna P Laakkonen

Academy of Finland (287478)

  • Minna U Kaikkonen

Academy of Finland (294073)

  • Minna U Kaikkonen

Ella and Georg Ehnrooth foundation

  • Johanna P Laakkonen

CoE of Cardiovascular and Metabolic Disease (307402)

  • Seppo Ylä-Herttuala

GeneCellNano Flagship Program (337120)

  • Johanna P Laakkonen

GeneCellNano Flagship Program (337120)

  • Seppo Ylä-Herttuala

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal experiments were approved by National Experimental Animal Board of Finland (Decision No Esavi-2019-004672) and carried out in accordance with guidelines of the Finnish Act on Animal Experimentation.

Human subjects: Patient sample collection was approved by the Ethical Committee of the Helsinki University hospital, Helsinki, Finland (Decision No 127/13/03/02/2010 and No 1394/2020). Control sample collection was approved by the Research Ethics Committee of the Northern Savo Hospital District, Kuopio, Finland (Decision No 139/2015). Umbilical cord collection for HUVEC isolation was performed with approval from the Research Ethics Committee of the Northern Savo Hospital District, Kuopio, Finland (Decision No 341/2015). Informed consent, and consent to publish, was obtained from all patients included in the study.

Copyright

© 2023, Jauhiainen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 857
    views
  • 119
    downloads
  • 2
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Suvi Jauhiainen
  2. Henna Ilmonen
  3. Pia Vuola
  4. Heta Rasinkangas
  5. Heidi H Pulkkinen
  6. Sara Keränen
  7. Miika Kiema
  8. Jade J Liikkanen
  9. Nihay Laham Karam
  10. Svetlana Laidinen
  11. Mustafa Beter
  12. Einari Aavik
  13. Kimmo Lappalainen
  14. Jouko Lohi
  15. Johanna Aronniemi
  16. Tiit Örd
  17. Minna U Kaikkonen
  18. Päivi Salminen
  19. Erkki Tukiainen
  20. Seppo Ylä-Herttuala
  21. Johanna P Laakkonen
(2023)
ErbB signalling is a potential therapeutic target for vascular lesions with fibrous component
eLife 12:e82543.
https://doi.org/10.7554/eLife.82543

Share this article

https://doi.org/10.7554/eLife.82543

Further reading

    1. Cancer Biology
    2. Cell Biology
    Kourosh Hayatigolkhatmi, Chiara Soriani ... Simona Rodighiero
    Tools and Resources

    Understanding the cell cycle at the single-cell level is crucial for cellular biology and cancer research. While current methods using fluorescent markers have improved the study of adherent cells, non-adherent cells remain challenging. In this study, we addressed this gap by combining a specialized surface to enhance cell attachment, the FUCCI(CA)2 sensor, an automated image analysis pipeline, and a custom machine learning algorithm. This approach enabled precise measurement of cell cycle phase durations in non-adherent cells. This method was validated in acute myeloid leukemia cell lines NB4 and Kasumi-1, which have unique cell cycle characteristics, and we tested the impact of cell cycle-modulating drugs on NB4 cells. Our cell cycle analysis system, which is also compatible with adherent cells, is fully automated and freely available, providing detailed insights from hundreds of cells under various conditions. This report presents a valuable tool for advancing cancer research and drug development by enabling comprehensive, automated cell cycle analysis in both adherent and non-adherent cells.

    1. Cell Biology
    Fatima Tleiss, Martina Montanari ... C Leopold Kurz
    Research Article

    Multiple gut antimicrobial mechanisms are coordinated in space and time to efficiently fight foodborne pathogens. In Drosophila melanogaster, production of reactive oxygen species (ROS) and antimicrobial peptides (AMPs) together with intestinal cell renewal play a key role in eliminating gut microbes. A complementary mechanism would be to isolate and treat pathogenic bacteria while allowing colonization by commensals. Using real-time imaging to follow the fate of ingested bacteria, we demonstrate that while commensal Lactiplantibacillus plantarum freely circulate within the intestinal lumen, pathogenic strains such as Erwinia carotovora or Bacillus thuringiensis, are blocked in the anterior midgut where they are rapidly eliminated by antimicrobial peptides. This sequestration of pathogenic bacteria in the anterior midgut requires the Duox enzyme in enterocytes, and both TrpA1 and Dh31 in enteroendocrine cells. Supplementing larval food with hCGRP, the human homolog of Dh31, is sufficient to block the bacteria, suggesting the existence of a conserved mechanism. While the immune deficiency (IMD) pathway is essential for eliminating the trapped bacteria, it is dispensable for the blockage. Genetic manipulations impairing bacterial compartmentalization result in abnormal colonization of posterior midgut regions by pathogenic bacteria. Despite a functional IMD pathway, this ectopic colonization leads to bacterial proliferation and larval death, demonstrating the critical role of bacteria anterior sequestration in larval defense. Our study reveals a temporal orchestration during which pathogenic bacteria, but not innocuous, are confined in the anterior part of the midgut in which they are eliminated in an IMD-pathway-dependent manner.